Briumvi (ublituximab-xiiy)

Adult Dosing .

Dosage forms:  INJ

Special Note

[drug name clarification]

Info: nonproprietary name = ublituximab-xiiy

multiple sclerosis, relapsing forms

[1st course]

Dose: 150 mg IV x1; Info: for patients with clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease; premed with corticosteroid 30min before and antihistamine 30-60min before infusion; consider premed with antipyretic

[2nd course]

Dose: 450 mg IV x1; Start: 2wk after 1st course; Info: for patients with clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease; premed with corticosteroid 30min before and antihistamine 30-60min before infusion; consider premed with antipyretic

[subsequent courses]

Dose: 450 mg IV x1 q24wk; Start: 24wk after 1st course; Info: for patients with clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease; premed with corticosteroid 30min before and antihistamine 30-60min before each infusion; consider premed with antipyretic

renal dosing

[see below]

mild impairment: no adjustment; moderate-severe impairment: not defined

HD/PD: not defined

hepatic dosing

[see below]

mild impairment: no adjustment; moderate-severe impairment: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.